Morning Brief — Wednesday, August 26, 2026

Market Overview

Markets are treading water in mixed pre-market action ahead of the day’s two biggest events: NVIDIA’s Q2 earnings after the close and the PCE inflation print this morning. Treasury yields have pulled back meaningfully, with the 10-year dipping ~7bps to 4.63%, offering some relief for growth names. The retail earnings wave continues to dominate individual stock action, with ANF’s tariff-refund-fueled blowout and DKS’s post-earnings collapse telling two very different stories about the consumer.

Claude’s Call

FLAT-to-UP — The yield retreat gives growth stocks a modest tailwind and NVDA earnings expectations are high but not euphoric (55% bullish on WSB is hardly a crowded long), suggesting a muted grind higher unless PCE prints hot; position sizing stays tight into the close given the binary NVDA event risk.

Top Movers

ANF (+27.1%) — $138.40 → $158.14 (+14.3% upside) Thesis: This is the real deal — ANF reported $4.17 EPS vs. the $1.80–$2.00 guided range, a +24% earnings surprise driven in large part by tariff refunds that management didn’t signal clearly in prior guidance. Revenue beat by ~2%, and full-year guidance was raised. The stock has now broken to a fresh 6-month high, trading at the exact 6mo swing high of $139.41, which means it is in price discovery territory. This isn’t sector sympathy — it’s a genuine fundamental re-rating. The tariff refund is a one-time tailwind, but the raised full-year guide suggests the underlying business (not just the refund) is healthy. RSI at 36 seems anomalous given the move — this is likely a data artifact; treat with caution — but the fib extension at $158.14 is the clean next target. Levels: Exit at Fib 1.272 extension of $158.14. Support at Fib 23.6% retracement $123.17; SMA-50 at $99.31 is deep-stop territory.

PLAB (+17.5%) — $34.44 → $38.02 (+10.4% upside) Thesis: Photronics delivered a genuine earnings beat — non-GAAP EPS of $0.50 vs. $0.40 consensus (+25% surprise), revenue up 2.7% YoY to $216M vs. estimates, and next-quarter guidance of $217M came in 0.6% above Street. The CEO cited recovery of semiconductor design releases that had been temporarily delayed in Q2 — this is a demand timing pull-forward, not demand destruction, which is bullish. Volume is running 2x average, which is the strongest vol confirmation on the entire gainers list today. Technically, PLAB has been in a sharp downtrend from its $54.96 6-month high, so this bounce is coming off deeply oversold conditions near the 6-month low ($27.55). The stock still sits well below all major fib retracement levels, which actually means there’s significant overhead resistance ahead. Levels: Exit at Fib 61.8% retracement of $38.02 (first realistic resistance). Support at SMA-50 ($30.86) and 20-day low ($29.32).

MRNA (+14.4%) — $158.83 → $174.38 (prior 6mo high, +9.8% upside) Thesis: The +152% weekly move is the headline but the story is real — late-stage trial data showed Moderna/Merck’s intismeran autogene + Keytruda combination was significantly more effective at preventing skin cancer recurrence than Keytruda alone. This is a legitimate pipeline catalyst, not a pump. Wolfe Research upgraded MRNA to Peer Perform from Underperform following the data, adding institutional credibility. The stock has rallied from a 6-month low of $45.37 to $158.83 — an extraordinary move — but it remains below the 6-month high of $174.38. The fib 23.6% support at $143.93 is the key level to watch on any pullback; a hold above that confirms the bull case. Valuation comps show MRNA screens as “CHEAP” vs. peers on forward P/E (though it’s negative), which reflects how depressed expectations were entering this week. Levels: Exit at 6-month high of $174.38. Support at Fib 23.6% ($143.93); below that, $125.10 (Fib 38.2%).

RUM (+9.3%) — $10.23 → $11.74 (+14.8% upside) Thesis: RUM Group announced a six-year, $13.7B GPU services agreement with an unnamed U.S. cloud customer tied to its Maysville, Georgia data center — this is genuinely transformative if it executes, but the unnamed customer and under-construction facility are major red flags. The warrant structure (50M+ shares at $0.01 vesting with purchases) creates meaningful dilution risk as the deal scales. The stock is now at the 6-month high of $10.23, having run +64% in a month. Technically, the fib 1.272 extension target of $11.74 is achievable, but chasing here means you’re buying the top with massive execution and financing uncertainty. Treat this as a “see-the-whites-of-their-eyes” story — wait for the customer to be named, the facility to come online, or a meaningful pullback before building a position. Levels: Exit at Fib 1.272 extension $11.74. Support at Fib 23.6% $8.92; SMA-50 at $6.76 is the real floor.

CDLR (+8.6%) — $26.04 → $31.87 (+22.4% upside) Thesis: Cadeler’s H1 2026 results showed revenue surging 432% and the company just completed the He Dreiht 960MW offshore wind installation — a tangible operational milestone. The $2.5B backlog is real contracted revenue, and the MENCK acquisition expands capabilities. Volume is running 2.15x average (second highest on the list alongside PLAB), which is meaningful confirmation. This is a picks-and-shovels play on offshore wind buildout — a secular theme, not a cyclical bounce. The stock has been in a 90-day downtrend (down ~20%) and today’s move is a bounce off the 6-month low area; it remains well below its 6-month high of $29.57 and all major fib retracements, meaning there’s substantial room to recover. Levels: Exit at Fib 1.272 extension $31.87 or prior resistance at $29.57. Support at 20-day low $21.17; SMA-50 at $22.74.

SMCI (+9.4%) — $38.46 → $43.17 (+12.3% upside) Thesis: Super Micro is riding a Cisco partnership announcement (dense GPU systems + liquid cooling), sector tailwinds ahead of NVDA earnings, and technical momentum from deeply oversold levels. The stock had collapsed from $50.17 to $20.53 in the 6-month swing — today’s bounce comes from deeply washed-out territory. RSI at 62 is the only name on the gainers list showing a genuinely elevated reading, which means momentum is building but not yet overbought. The NVDA earnings tonight are the key binary: a NVDA beat likely adds fuel here; a miss could take SMCI back to $31.85 (Fib 61.8% support) quickly. This is a high-conviction sector trade but with a hard timer — manage through tonight’s print. Levels: Exit at Fib 38.2% retracement $38.85 or Fib 23.6% at $43.17. Support at Fib 61.8% $31.85; SMA-50 at $30.85.

SMMT (+10.6%) — $14.78 → $17.76 (+20.2% upside) Thesis: Summit Therapeutics is rallying on partner Akeso reporting Phase III success in a second tumor type for ivonescimab — this compounds the NSCLC data already driving the stock and confirms the drug’s broader oncology potential. Bernstein SocGen also upgraded the stock yesterday (Underperform → Market Perform, target raised to $11) which is a low bar but still removes an active bear from the table. The stock has pulled back significantly from its $26.38 6-month high to current levels, so this is a bounce play in a beaten-down biotech with a genuinely improving data narrative. The Fib 61.8% support at $17.76 is the near-term resistance that becomes the target. Levels: Exit at Fib 61.8% retracement of the 6mo move at $17.76. Support at SMA-50 ($14.09) and 20-day low ($12.43).

Headlines to Watch

  • Abercrombie & Fitch Q2 beat driven by tariff refunds — The $4.17 EPS vs. $1.80–$2.00 guide is extraordinary, but investors must parse how much of the beat is sustainable business vs. one-time tariff refund; the raised full-year guide suggests underlying health, but the stock is now at 6-month highs and the one-time nature of the refund limits re-rating upside.

  • NVIDIA earnings tonight — the market’s keystone event — With 488 WSB mentions and mixed sentiment, NVDA’s Q2 report will set the tone for the entire AI trade; any guidance conservatism could cascade into SMCI, PLAB, and semiconductor names that have been pre-rallying in anticipation.

  • PCE inflation print this morning — Treasury yields already dropped 7bps in anticipation; a soft print confirms the Fed’s path toward cuts and supports growth/tech; a hot print could reverse the overnight yield rally and pressure the Nasdaq before NVDA even reports.

  • RUM Group $13.7B unnamed-customer GPU deal — The contract is massive on paper, but the unnamed U.S. cloud customer, under-construction facility, and $0.01 warrant structure covering 50M+ shares should keep sophisticated investors skeptical until the customer is disclosed and financing secured.

  • Dick’s Sporting Goods (DKS) post-earnings collapse — Down sharply despite a beat; with 80% bullish WSB sentiment and the stock sitting at its 6-month low of $122.75, this is either a buying opportunity or a consumer warning shot — worth watching for read-through to retail sector health.

  • Moderna +152% weekly move — melanoma vaccine catalyst — The intismeran autogene + Keytruda Phase III data is the most significant pharmaceutical catalyst of the week; a genuine efficacy signal in skin cancer with broad blockbuster potential if Phase III leads to FDA filing.

  • Kohl’s falls 6% despite raised guidance and $150M tariff refund — Same playbook as ANF but the market is punishing KSS — the distinction appears to be margin quality; this is a warning that tariff refund beats are not created equal and the market is already discounting one-time items.

Claude’s Top Picks

ANF (+27.1% today, +31.3% week) — $138.40 → $158.14 (+14.3% upside) Valuation: No forward P/E comp provided, but the guidance raise and margin surprise justify a premium to specialty retail peers. Upside: Raised full-year guidance combined with a genuine earnings surprise (not just a tariff refund) signals the business has regained operational momentum; fib 1.272 extension at $158.14 is the clean next target in price discovery territory. Risk: The tariff refund is a one-time item — if Q3 strips that out and the underlying margin structure disappoints, the stock could give back the entire gap rapidly; stop below $123.17 (Fib 23.6%).

PLAB (+17.5% today, +12.2% week) — $34.44 → $38.02 (+10.4% upside) Valuation: No direct comp provided, but photomask manufacturers typically trade at modest multiples; the 6-month selloff from $54.96 suggests the stock was de-rated well beyond the fundamental slowdown. Upside: 2x volume confirmation, genuine earnings beat, and next-quarter guidance above consensus — this is the trifecta for a sustained recovery trade; the demand timing recovery management cited points to Q4 strength. Risk: The stock is still in a structural downtrend from $54.96 and the 6-month fib retracements (starting at $38.02) represent stacked resistance; this is a bounce trade, not a trend reversal.

CDLR (+8.6% today, +11.7% week) — $26.04 → $31.87 (+22.4% upside) Valuation: Offshore wind installation is a niche with limited direct comps, but a 432% revenue surge and $2.5B backlog at this market cap screens as dramatically undervalued relative to revenue growth. Upside: The secular offshore wind buildout is a multi-year story, the MENCK acquisition adds a new revenue stream, and the volume confirmation (2.15x average) is the highest real-money conviction signal on the list today. Risk: Offshore wind is capital-intensive and politically sensitive — any permitting slowdowns, contract renegotiations, or integration hiccups on MENCK could pressure the stock; also watch for further share issuance to fund the newbuild program.

SMMT (+10.6% today, +12.7% week) — $14.78 → $17.76 (+20.2% upside) Valuation: Pre-revenue biotech; valuation is entirely pipeline-driven, but the ivonescimab multi-indication Phase III success meaningfully de-risks the thesis compared to a year ago when the stock was near $26. Upside: A second Phase III win for the partner drug dramatically increases the probability of a broad label and potential deal with a major pharma — the stock is still 44% below its 6-month high with a real catalyst behind it now. Risk: This is a binary biotech — any FDA feedback, regulatory delay on the NSCLC NDA review, or partner execution risk at Akeso could erase this move; SMA-50 at $14.09 is the critical hold level.

SMCI (+9.4% today, +2.8% week) — $38.46 → $43.17 (+12.3% upside) Valuation: No forward P/E provided, but SMCI’s deep discount to its 6-month high and the AI infrastructure cycle suggest the market was pricing in existential accounting/governance risk that has since partially resolved. Upside: Cisco partnership validates the AI server stack story, and if NVDA beats tonight, SMCI is the most direct beneficiary in the gainers list as a primary GPU server vendor. Risk: Hard binary on NVDA tonight — a disappointing NVDA print or weak guidance on AI server demand hits SMCI disproportionately; RSI at 62 means it’s no longer deeply oversold, limiting the risk-reward vs. earlier in the week.

Avoid

RUM (+9.3% today, +26.3% week) — Stock is at its 6-month high of $10.23 with a 64% monthly gain; the $13.7B deal involves an unnamed customer and an unbuilt facility, creating massive execution risk at a price that has already priced in success — this is not the entry point, and the 50M+ share warrant overhang is a structural headwind.

MRNA (+14.4% today, +152.3% week) — The weekly return of 152% means the stock has tripled in five sessions from $45 to $158; while the melanoma vaccine data is real, this move is already past the Fib 23.6% support level at $143.93 on the way up — chasing here after a 3x move into the 6-month high at $174 is a -10% drawdown risk for a +10% reward, and biotech data excitement frequently gets sold into over 30-60 days.

CRML (+21.4% today, +31.7% week) — Classic “government funding announcement” rare-earth pump with no specific company contract — the $1.55B package is sector-wide, there’s a rumored European lithium merger that “keeps surfacing in trader circles” as the price catalyst (unverified per the news itself), and the stock has a 3-year total shareholder return of -38%; Trump policy tailwinds for rare earths historically fade within 48-72 hours without a binding company-specific contract.

WSB Sentiment Check

NVDA — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — 55% bullish is actually below the typical NVDA hype level, which suggests the street isn’t leaning into this print with reckless conviction; the stock sits at $210.90, between SMA-50 ($207.78) and the Fib 38.2% retracement ($208.54) — a technically reasonable entry, but the real trade is to let the print happen tonight and then react rather than front-run with size.

DKS — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — The stock just collapsed to a fresh 6-month low of $122.75 (down from $239.17) and 80% WSB bullishness at the absolute price low of a 49% drawdown is a “catching falling knives” setup; the market clearly sees something broken in the margin story that justifies the sell-the-news reaction despite the headline beat — wait for a base to form before trusting the 80% bulls here.

SNDK — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — SanDisk at $1,463 is well below its 6-month high of $2,335 and sitting below the Fib 50% support of $1,431 — it’s structurally in a downtrend from peak and 55% bullish feels about right for a recovering memory play; the mixed sentiment reflects genuine uncertainty about whether the NAND recovery cycle has enough legs to reclaim prior highs.

META — WSB says: BULLISH (80% bullish) Claude says: AGREE — Meta at $581 is sitting right at the Fib 61.8% support of $587 (just slightly below), with SMA-50 overhead at $592; 80% bullishness at a technical support level after a pullback from $688 is a legitimate thesis — this is the textbook “buy the dip at the golden pocket” setup and Meta’s fundamentals (ad revenue, Llama AI monetization) support the bull case.

MU — WSB says: BEARISH (30% bullish) Claude says: AGREE — Micron at $932 is below both the Fib 23.6% support ($1,002) and the SMA-50 ($958), in a clear downtrend from the $1,213 6-month high; 30% bullish from WSB is rare and usually signals a genuinely broken chart — the memory cycle has peaked for this upcycle and without a new catalyst (NVDA beat tonight could be one), the path of least resistance is toward $872 (Fib 38.2%).

Earnings Scorecard

ANF — BEAT by ~+107% on EPS ($4.17 vs. ~$1.90 midpoint) | Stock: +27.1% | Reported: Aug 26, Before Open The reaction is justified but may be slightly overdone intraday given that the core driver — a tariff refund — is one-time; raised full-year guidance is what earns the sustained re-rating, and the stock technically deserves to hold the gap. Buy-the-first-dip thesis intact above $123.

DY (Dycom) — BEAT on both EPS and Revenue | Stock: -8.5% | Reported: Recent Sell-the-rip despite the beat — Dycom’s AI infrastructure demand commentary was strong, but the -8.5% reaction on a beat suggests the stock was priced for perfection and guidance either disappointed on margins or raised concerns about project timing; this is a buy-the-dip candidate on a further pullback but not yet.

SMTC (Semtech) — Record Revenue / Beat | Stock: +7.8% | Reported: Recent Justified reaction — data center momentum at Semtech is a clean AI infrastructure read-through, and the +7.8% on a record revenue print with positive guidance is a measured, healthy response; not overextended, and worth watching for a pullback entry toward the prior support zone.

BOX — BEAT, record AI-driven bookings, raised guidance | Stock: +3.4% | Reported: Recent Under-reacted — record AI bookings and raised guidance with only a +3.4% response suggests the market wants more proof of monetization velocity (which UBS explicitly flagged); the muted reaction is not bearish but means the stock isn’t a momentum buy today.

CRWD (CrowdStrike) — REPORTED ($-0.04 EPS) | Stock: -0.7% | Reported: Recent Effectively flat reaction on what appears to be a reported loss quarter — with analyst target at $210.53 and the stock presumably well below that (not in the technical data), the lack of enthusiasm suggests lingering concerns from the 2025 outage recovery narrative; neutral read.

ADSK (Autodesk) — REPORTED ($6.86 EPS) | Stock: -1.1% | Reported: Recent Mild sell-the-news on what sounds like a solid print — the -1.1% reaction with analyst target at $314 suggests the move was already priced in; subscription-led momentum is well-understood and the stock wasn’t cheap going in. Not a buy today.

OKTA — REPORTED ($1.38 EPS) | Stock: -1.1% | Reported: Recent Mild negative reaction with analyst target at $146 — cybersecurity names are being held to an exceptionally high bar (“priced for big AI growth” per the headline), and OKTA’s identity-security story hasn’t fully translated into the AI upsell narrative the market wants; hold-and-wait.

AFRM (Affirm) — REPORTED ($1.10 EPS) | Stock: -1.2% | Reported: Recent Slightly concerning — Klarna cut guidance recently and BNPL sentiment is soft; the -1.2% on a $1.10 print suggests the market is focused on category-level concerns over company-specific beats; not a buy-the-dip until macro consumer data improves.

M (Macy’s) — REPORTED ($2.42 EPS) | Stock: -0.2% | Reported: Recent Essentially flat reaction — Macy’s continues to be a “show me” story with analyst target at $22.95; no meaningful reaction either way means this is dead money until there’s a structural catalyst (real estate monetization, brand recovery evidence). Avoid.

This brief is for informational and educational purposes only. Not investment advice. All technical levels and targets are based on historical price data and should be verified before trading.